Parallax Volatility Advisers, L.P. Vertex Pharmaceuticals Inc Call Options Transaction History

Parallax Volatility Advisers, L.P.

$45.1 Billion
Q2 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $12.6 Million - $15.6 Million	-32,200 Reduced 81.73%	7,200 $3.37 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $15.8 Million - $17.3 Million	38,800 Added 6466.67%	39,400 $16.5 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $3.43 Million - $4.11 Million	-10,000 Reduced 94.34%	600 $244,000
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $3.25 Million - $3.48 Million	9,600 Added 960.0%	10,600 $3.69 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $62,884 - $70,382	-200 Reduced 16.67%	1,000 $351,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $4.22 Million - $4.81 Million	-14,900 Reduced 92.55%	1,200 $378,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $571,520 - $642,960	2,000 Added 14.18%	16,100 $4.65 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $19.8 Million - $22.1 Million	-72,300 Reduced 83.68%	14,100 $4.08 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $78.9 Million - $98.3 Million	-336,000 Reduced 79.55%	86,400 $24.3 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $93.5 Million - $110 Million	422,400 New	422,400 $110 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $89.7 Million - $113 Million	-506,800 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $80.4 Million - $101 Million	454,200 Added 863.5%	506,800 $111 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $11.9 Million - $13.4 Million	-65,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $9.54 Million - $10.7 Million	52,600 New	52,600 $9.54 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $12.3 Million - $14.5 Million	65,800 New	65,800 $13.3 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $13.2 Million - $15.4 Million	-64,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $6.29 Million - $7.34 Million	30,400 Added 90.48%	64,000 $13.8 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $6.96 Million - $9.28 Million	33,600 New	33,600 $7.94 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $3.08 Million - $4.11 Million	-14,900 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $5.42 Million - $6.43 Million	-21,200 Reduced 58.73%	14,900 $4.05 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $4.35 Million - $5.71 Million	19,300 Added 114.88%	36,100 $10.5 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $1.88 Million - $2.53 Million	11,300 Added 205.45%	16,800 $3.68 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $1.25 Million - $1.4 Million	-7,500 Reduced 57.69%	5,500 $931,000
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $1.6 Million - $1.85 Million	9,700 Added 293.94%	13,000 $2.38 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $5.63 Million - $6.7 Million	-34,400 Reduced 91.25%	3,300 $607,000
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $5.73 Million - $7.25 Million	37,700 New	37,700 $6.25 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

Capital World Investors Los Angeles, CA

26.7M
Shares

$13.4 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$11.5 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.89 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.29 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.

Account